
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd demonstrates a positive outlook driven by expanded supply agreements and leadership appointments aimed at enhancing North American growth, particularly through its proprietary rhCollagen products. The company's innovative Collink.3D technology is poised to differentiate it within the competitive landscape, especially in the fields of regenerative medicine and aesthetic applications, potentially unlocking significant market opportunities. Moreover, the establishment of a U.S.-based logistics center is expected to bolster sales of BioInk and rhCollagen, alongside new distribution agreements in Europe that will further strengthen the company's market presence and financial performance.
Bears say
CollPlant Biotechnologies Ltd faces a challenging financial outlook due to stagnant revenue growth across its key markets, particularly in the United States, where the company relies heavily on its regenerative and aesthetic medicine products. Additionally, the sales performance of the BioInk product and rhCollagen for medical aesthetics has not met expectations, indicating potential difficulties in market penetration and competitiveness. The company's reliance on income from business collaborators further exposes it to risks associated with partnership performance and market fluctuations, limiting its financial stability and growth potential.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares